You are here: Industry Insights > CX-5461

News List

Safety concerns raised for neuroblastoma candidate drug WorldPharmaNews
November 10, 2021
St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461.
Senhwa Biosciences Receives US FDA 'Study May Proceed' Letter to Treat BRCA2+ or PALB2+ Solid Tumors With CX-5461 prnasia
December 24, 2020
Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, announced that it has received a "Study May Proceed" letter from the US Food and Drug ...
Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations prnasia
November 26, 2020
Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, announced that it has submitted multiple Investigational New Drug (IND) applications to ...
Senhwa Biosciences Reports Positive Phase 1 Data of CX-5461 in Patients With Advanced Solid Tumors at 2019 SABCS prnasia
December 16, 2019
Evidence of human efficacy observed in patients with specific biomarkers and refractory to standard treatments including platinum and other chemotherapeutics